ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Neuroscience

Lilly and Roche antiamyloid drugs fail in trial of early-onset Alzheimer’s trial

by Ryan Cross
February 15, 2020 | APPEARED IN VOLUME 98, ISSUE 7

Yet again, antibodies designed to target β-amyloid have failed. Researchers at Washington University in St. Louis tested Roche’s gantenerumab, Eli Lilly and Company’s solanezumab, or a placebo in 194 people with a genetic mutation that causes early-onset Alzheimer’s. Neither antibody slowed memory loss or cognitive decline. Both drugs have failed in Alzheimer’s trials before, but Lilly and Roche will continue to test them in people with late-onset Alzheimer’s not caused by genetic mutations.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment